نتایج جستجو برای: mycn

تعداد نتایج: 1228  

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2016
Anton Henssen Kristina Althoff Andrea Odersky Anneleen Beckers Richard Koche Frank Speleman Simon Schäfers Emma Bell Maike Nortmeyer Frank Westermann Katleen De Preter Alexandra Florin Lukas Heukamp Annika Spruessel Kathy Astrahanseff Sven Lindner Natalie Sadowski Alexander Schramm Lucile Astorgues-Xerri Maria E Riveiro Angelika Eggert Esteban Cvitkovic Johannes H Schulte

PURPOSE Targeting BET proteins was previously shown to have specific antitumoral efficacy against MYCN-amplified neuroblastoma. We here assess the therapeutic efficacy of the BET inhibitor, OTX015, in preclinical neuroblastoma models and extend the knowledge on the role of BRD4 in MYCN-driven neuroblastoma. EXPERIMENTAL DESIGN The efficacy of OTX015 was assessed in in vitro and in vivo models...

2014
Yusuke Suenaga S. M. Rafiqul Islam Jennifer Alagu Yoshiki Kaneko Mamoru Kato Yukichi Tanaka Hidetada Kawana Shamim Hossain Daisuke Matsumoto Mami Yamamoto Wataru Shoji Makiko Itami Tatsuhiro Shibata Yohko Nakamura Miki Ohira Seiki Haraguchi Atsushi Takatori Akira Nakagawara

The rearrangement of pre-existing genes has long been thought of as the major mode of new gene generation. Recently, de novo gene birth from non-genic DNA was found to be an alternative mechanism to generate novel protein-coding genes. However, its functional role in human disease remains largely unknown. Here we show that NCYM, a cis-antisense gene of the MYCN oncogene, initially thought to be...

Journal: :Cancer research 2005
Giuseppe Giannini Fabio Cerignoli Massimiliano Mellone Isabella Massimi Cinzia Ambrosi Christian Rinaldi Carlo Dominici Luigi Frati Isabella Screpanti Alberto Gulino

High mobility group A1 (HMGA1) is an architectural transcription factor and a putative protoncogene. Deregulation of its expression has been shown in most human cancers. We have previously shown that the expression of the HMGA family members is deregulated in neuroblastoma cell lines and primary tumors. On retinoic acid (RA) treatment of MYCN-amplified neuroblastoma cell lines, HMGA1 decreases ...

2013
Miao Wang Chunju Zhou Rongqin Cai Yong Li Liping Gong

BACKGROUND Amplification of MYCN oncogene is an established marker indicating aggressive tumor progression of neuroblastoma (NBL). But copy number analyses of MYCN gene in ganglioneuroblastoma (GNBL) and ganglioneuroma(GN) is poorly described in the literature. In the study, we evaluated the copy number aberrations of MYCN gene in clinical samples of NBLs, GNBLs and GNs and analyzed their assoc...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2011
Jesmin Akter Atsushi Takatori Md Shamim Hossain Toshinori Ozaki Atsuko Nakazawa Miki Ohira Yusuke Suenaga Akira Nakagawara

PURPOSE Our previous study showed that expression of NLRR3 is significantly high in favorable neuroblastomas (NBL), whereas that of NLRR1 is significantly high in unfavorable NBLs. However, the molecular mechanism of transcriptional regulation of NLRR3 remains elusive. This study was undertaken to clarify the transcriptional regulation of NLRR3 and its association with the prognosis of NBL. E...

Journal: :Proceedings of the National Academy of Sciences of the United States of America 1994
R Corvi L C Amler L Savelyeva M Gehring M Schwab

Amplification of the human N-myc protooncogene, MYCN, is frequently seen either in extrachromosomal double minutes or in homogeneously staining regions of aggressively growing neuroblastomas. MYCN maps to chromosome 2 band p23-24, but homogeneously staining regions have never been observed at this band, suggesting transposition of MYCN during amplification. We have employed fluorescence in situ...

2014
Elizabeth Latimer Glenn Anderson Neil James Sebire

BACKGROUND Neuroblastoma is the most common solid tumour of infancy and is responsible for 15% of childhood cancer deaths. Presence of amplified MYCN in neuroblastoma is associated with poor prognosis and rapid tumour progression. The aim of this study was to examine and compare the ultrastructural features of high-risk MYCN amplified neuroblastomas, with lower-risk non-MYCN amplified tumours. ...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2009
Jessica Theissen Marc Boensch Ruediger Spitz David Betts Sabine Stegmaier Holger Christiansen Felix Niggli Freimut Schilling Manfred Schwab Thorsten Simon Frank Westermann Frank Berthold Barbara Hero

PURPOSE MYCN amplification is an important therapy-stratifying marker in neuroblastoma. Fluorescence in situ hybridization with signal detection on the single-cell level allows a critical judgement of MYCN intratumoral heterogeneity. EXPERIMENTAL DESIGN The MYCN status was investigated by fluorescence in situ hybridization at diagnosis and relapse. Heterogeneity was defined as the simultaneou...

2016
Zhenze Zhao Xiuye Ma Spencer D. Shelton Derek C. Sung Monica Li Daniel Hernandez Maggie Zhang Michael D. Losiewicz Yidong Chen Alexander Pertsemlidis Xiaojie Yu Yuanhang Liu Liqin Du

MYCN amplification is the most common genetic alteration in neuroblastoma and plays a critical role in neuroblastoma tumorigenesis. MYCN regulates neuroblastoma cell differentiation, which is one of the mechanisms underlying its oncogenic function. We recently identified a group of differentiation-inducing microRNAs. Given the demonstrated inter-regulation between MYCN and microRNAs, we specula...

Journal: :Proceedings of the National Academy of Sciences of the United States of America 2004
Loen M Hansford Wayne D Thomas Joanna M Keating Catherine A Burkhart Anne E Peaston Murray D Norris Michelle Haber Patricia J Armati William A Weiss Glenn M Marshall

The mechanisms causing persistence of embryonal cells that later give rise to tumors is unknown. One tumorigenic factor in the embryonal childhood tumor neuroblastoma is the MYCN protooncogene. Here we show that normal mice developed neuroblast hyperplasia in paravertebral ganglia at birth that completely regressed by 2 weeks of age. In contrast, ganglia from MYCN transgenic (TH-MYCN) mice demo...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید